SNDX News and Press, Syndax Pharmaceuticals Inc. From 11/16/21

The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Syndax Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call Presentation

Syndax Pharmaceuticals, Inc. (SNDX) Q3 2021 Earnings Conference Call November 15, 2021 4:30 PM ET Company Participants Melissa Forst - Argot Partners, Investor Relations Briggs Morrison - Chief Executive Officer Michael Metzger - President, Chief Operating Officer and Director Anjali Ganguli ...

Syndax Pharmaceuticals (NASDAQ:SNDX): Q3 GAAP EPS of -$0.40 misses by $0.35. Revenue of $12.38M (+3157.9% Y/Y) misses by $17.03M. Press Release For further details see: Syndax Pharmaceuticals EPS misses by $0.35, misses on revenue

Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update - Initiated pivotal Phase 2 portion of SNDX-5613 AUGMENT-101 trial in patients with NPM1 and MLLr acute leukemias - - Entered global collaboration with Incyte to dev...

Syndax to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 15, 2021 PR Newswire WALTHAM, Mass. , Nov. 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clini...

Syndax Pharmaceuticals (SNDX -16.0%) has dropped over 10% after the company shared updated data from a Phase 1/2 trial for SNDX-5613 in patients with mutant relapsed/refractory (R/R) acute leukemias. In the AUGMENT-101 trial that included patients with MLLr and NPM1c mutation, the composite c...

Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical Programs During Oral Sessions at 63rd ASH Annual Meeting - Robust clinical activity with durable responses and no discontinuations due to treatment-related adverse events observed in Phase 1 po...

On a strong day for the equity market, cryptocurrencies also found buyers. The rise in the asset class gave a boost to stocks largely reliant on crypto strength. Marathon Digital (NASDAQ:MARA), Riot Blockchain (NASDAQ:RIOT), Silvergate (NYSE:SI), Bit Digital (NASDAQ:BTBT) and MicroStrategy (N...

Gainers: Aditxt (NASDAQ:ADTX) +22%, Synaptogenix (NASDAQ:SNPX) +17%, Shineco (NASDAQ:TYHT) +13%, SmileDirectClub (NASDAQ:SDC) +12%, Silverback Therapeutics (NASDAQ:SBTX) +9%. Losers: UpHealth (NYSE:UPH) -34%, Unity Biotechnology (NASDAQ:UBX)&#...

Puhui Wealth Investment (NASDAQ:PHCF) +55%. Red Cat Holdings RCAT +50% after subsidiary receives five-year contract with NASA Paltalk (NASDAQ:PALT) +36%. Vinco Ventures (NASDAQ:BBIG) +16%. VIZIO Holding (NYSE:VZIO) +10%. U.S. Energy (NASDAQ:USEG) +8%. Syndax Pharmaceuticals (NASDAQ:...